CY1105585T1 - Χρηση των πολυπεπτιδιων casb616 και πολυνουκλεοτιδιων για τη θεραπεια του καρκινου - Google Patents

Χρηση των πολυπεπτιδιων casb616 και πολυνουκλεοτιδιων για τη θεραπεια του καρκινου

Info

Publication number
CY1105585T1
CY1105585T1 CY20051100614T CY051100614T CY1105585T1 CY 1105585 T1 CY1105585 T1 CY 1105585T1 CY 20051100614 T CY20051100614 T CY 20051100614T CY 051100614 T CY051100614 T CY 051100614T CY 1105585 T1 CY1105585 T1 CY 1105585T1
Authority
CY
Cyprus
Prior art keywords
polynucleotides
treatment
cancer
casb616
polypeptides
Prior art date
Application number
CY20051100614T
Other languages
English (en)
Inventor
Carlota Vinals Y De Bassols
Original Assignee
Glaxosmithkline Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals S.A. filed Critical Glaxosmithkline Biologicals S.A.
Publication of CY1105585T1 publication Critical patent/CY1105585T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/82—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Catalysts (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)

Abstract

Χρήση των πολυπεπτιδίων CASB616 και πολυνουκλεοτιδίων στη διαγνωστική, και εμβόλια για την προφυλακτική και θεραπευτική αγωγή των καρκίνων, συγκεκριμένα των καρκίνων του κόλου, αυτοάνοσων νοσημάτων και συναφών παθήσεων.
CY20051100614T 1999-03-05 2005-05-18 Χρηση των πολυπεπτιδιων casb616 και πολυνουκλεοτιδιων για τη θεραπεια του καρκινου CY1105585T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9905124.5A GB9905124D0 (en) 1999-03-05 1999-03-05 Novel compounds
PCT/EP2000/001587 WO2000053216A2 (en) 1999-03-05 2000-02-28 Use of casb616 polypeptides and polynucleotides for cancer treatment

Publications (1)

Publication Number Publication Date
CY1105585T1 true CY1105585T1 (el) 2010-07-28

Family

ID=10849064

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20051100614T CY1105585T1 (el) 1999-03-05 2005-05-18 Χρηση των πολυπεπτιδιων casb616 και πολυνουκλεοτιδιων για τη θεραπεια του καρκινου

Country Status (23)

Country Link
US (1) US20050129717A1 (el)
EP (2) EP1162993B1 (el)
JP (1) JP2002538218A (el)
KR (1) KR20010102507A (el)
CN (1) CN1374869A (el)
AT (1) ATE292472T1 (el)
AU (1) AU766789B2 (el)
BR (1) BR0008784A (el)
CA (1) CA2362370A1 (el)
CY (1) CY1105585T1 (el)
CZ (1) CZ20013189A3 (el)
DE (1) DE60019273T2 (el)
ES (1) ES2238026T3 (el)
GB (1) GB9905124D0 (el)
HK (1) HK1043729B (el)
HU (1) HUP0200186A2 (el)
IL (1) IL145046A0 (el)
NO (1) NO20014292L (el)
NZ (1) NZ513837A (el)
PL (1) PL354143A1 (el)
PT (1) PT1162993E (el)
TR (1) TR200102577T2 (el)
WO (1) WO2000053216A2 (el)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6774223B2 (en) * 2000-06-28 2004-08-10 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating colon cancer
ES2392943T3 (es) * 2000-10-18 2012-12-17 Glaxosmithkline Biologicals S.A. Vacunas antitumorales
US20050276812A1 (en) 2004-06-01 2005-12-15 Genentech, Inc. Antibody-drug conjugates and methods
CN1446583A (zh) * 2002-11-29 2003-10-08 帕弗瑞生物技术(北京)有限公司 一种肿瘤免疫治疗及预防性疫苗的组成、制备、应用方案
SG195524A1 (en) 2003-11-06 2013-12-30 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
AU2005286607B2 (en) 2004-09-23 2011-01-27 Genentech, Inc. Cysteine engineered antibodies and conjugates
US8470980B2 (en) 2009-09-09 2013-06-25 Centrose, Llc Extracellular targeted drug conjugates
DK2528625T3 (da) 2010-04-15 2013-10-14 Spirogen Sarl Pyrrolobenzodiazepiner og konjugater deraf
CN114246952A (zh) 2010-06-08 2022-03-29 基因泰克公司 半胱氨酸改造的抗体和偶联物
US20120121615A1 (en) 2010-11-17 2012-05-17 Flygare John A Alaninyl maytansinol antibody conjugates
ES2567276T3 (es) 2011-05-12 2016-04-21 Genentech, Inc. Método de LC-MS/MS de monitoreo de múltiples reacciones para detectar anticuerpos terapéuticos en muestras de animales usando péptidos de cambio de marco
CN103987407B (zh) 2011-10-14 2016-08-24 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其偶联物
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
JP6392763B2 (ja) 2012-10-12 2018-09-19 エイディーシー・セラピューティクス・エス・アーＡｄｃ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｓａ ピロロベンゾジアゼピン−抗体結合体
ES2680153T3 (es) 2012-10-12 2018-09-04 Adc Therapeutics Sa Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas
ES2660029T3 (es) 2012-10-12 2018-03-20 Medimmune Limited Conjugados de anticuerpo-pirrolobenzodiazepinas
CA2885340C (en) 2012-10-12 2016-11-08 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
RS57694B1 (sr) 2012-10-12 2018-11-30 Adc Therapeutics Sa Pirolobenzodiazepin - anti-psma konjugati antitela
MX364327B (es) 2012-10-12 2019-04-23 Medimmune Ltd Conjugados del anticuerpo pirrolobenzodiazepina - anti-cd22.
HUE039329T2 (hu) 2012-10-12 2018-12-28 Adc Therapeutics Sa Pirrolobenzodiazepin-antitest konjugátumok
WO2014096365A1 (en) 2012-12-21 2014-06-26 Spirogen Sàrl Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
ES2658888T5 (es) 2012-12-21 2021-10-19 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas
NZ710745A (en) 2013-03-13 2019-03-29 Genentech Inc Pyrrolobenzodiazepines and conjugates thereof
AU2014230735B2 (en) 2013-03-13 2018-03-15 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
JP6340019B2 (ja) 2013-03-13 2018-06-06 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
EA201690195A1 (ru) 2013-08-12 2016-05-31 Дженентек, Инк. Конъюгатные соединения антитело-лекарство на основе димера 1-(хлорметил)-2,3-дигидро-1h-бензо[e]индола и способы применения и лечения
WO2015052532A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
MX371092B (es) 2013-12-16 2020-01-16 Genentech Inc Compuestos peptidomimeticos y conjugados de anticuerpo-farmaco de los mismos.
PE20161394A1 (es) 2013-12-16 2017-01-06 Genentech Inc Compuestos peptidomimeticos y sus conjugados de anticuerpo-farmaco
JP6980384B2 (ja) 2013-12-16 2021-12-15 ジェネンテック， インコーポレイテッド １−（クロロメチル）−２，３−ジヒドロ−１ｈ−ベンゾ［ｅ］インドール二量体抗体−薬物コンジュゲート化合物、並びに使用及び処置の方法
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
BR112017003236A2 (pt) 2014-09-12 2017-11-28 Genentech Inc anticorpos elaborados com cisteína, conjugados de droga e anticorpos, método de preparação de conjugado de droga e anticorpo e composição farmacêutica
EP3191134B1 (en) 2014-09-12 2019-11-20 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CR20170099A (es) 2014-09-17 2017-07-19 Genentech Inc Pirrolobenzodiazepinas y conjugados de anticuerpos-disulfuro de las mismas
MX2017006770A (es) 2014-11-25 2018-02-09 Adc Therapeutics Sa Conjugados de pirrolobenzodiazepina y anticuerpo.
EP3226909A1 (en) 2014-12-03 2017-10-11 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
US20170315132A1 (en) 2016-03-25 2017-11-02 Genentech, Inc. Multiplexed total antibody and antibody-conjugated drug quantification assay
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
JP2019522633A (ja) 2016-05-20 2019-08-15 ジェネンテック， インコーポレイテッド Ｐｒｏｔａｃ抗体コンジュゲート及び使用方法
CN109313200B (zh) 2016-05-27 2022-10-04 豪夫迈·罗氏有限公司 用于表征位点特异性抗体-药物缀合物的生物分析性方法
WO2017214024A1 (en) 2016-06-06 2017-12-14 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
WO2018031662A1 (en) 2016-08-11 2018-02-15 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
WO2018065501A1 (en) 2016-10-05 2018-04-12 F. Hoffmann-La Roche Ag Methods for preparing antibody drug conjugates
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
PT3544636T (pt) 2017-02-08 2021-05-04 Medimmune Ltd Conjugados de anticorpos-pirrolobenzodiazepinas
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
WO2018192944A1 (en) 2017-04-18 2018-10-25 Medimmune Limited Pyrrolobenzodiazepine conjugates
KR20190141666A (ko) 2017-04-20 2019-12-24 에이디씨 테라퓨틱스 에스에이 항-axl 항체-약물 접합체로의 병용 요법
AU2018285562B2 (en) 2017-06-14 2024-01-18 Adc Therapeutics Sa Dosage regimes for the administration of an anti-CD19 ADC
ES2906965T3 (es) 2017-08-18 2022-04-21 Medimmune Ltd Conjugados de pirrolobenzodiazepina
WO2019060398A1 (en) 2017-09-20 2019-03-28 Ph Pharma Co., Ltd. ANALOGUES OF THAILANSTATINE
US11068545B2 (en) 2017-11-17 2021-07-20 Battelle Memorial Institute Spatial identification of assets using n-dimensional asset identifiers
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
TW202037381A (zh) 2018-10-24 2020-10-16 瑞士商赫孚孟拉羅股份公司 綴合化學降解誘導劑及使用方法
WO2020123275A1 (en) 2018-12-10 2020-06-18 Genentech, Inc. Photocrosslinking peptides for site specific conjugation to fc-containing proteins
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002530350A (ja) * 1998-11-20 2002-09-17 ジェネンテック・インコーポレーテッド 血管障害を処置するためのＥｐｈレセプターのアンタゴニストおよびアゴニストについての使用

Also Published As

Publication number Publication date
CN1374869A (zh) 2002-10-16
HUP0200186A2 (en) 2002-05-29
WO2000053216A2 (en) 2000-09-14
GB9905124D0 (en) 1999-04-28
JP2002538218A (ja) 2002-11-12
ATE292472T1 (de) 2005-04-15
EP1466616A2 (en) 2004-10-13
PT1162993E (pt) 2005-06-30
EP1466616A3 (en) 2004-12-01
NZ513837A (en) 2003-02-28
CA2362370A1 (en) 2000-09-14
AU2915300A (en) 2000-09-28
DE60019273D1 (de) 2005-05-12
NO20014292D0 (no) 2001-09-04
AU766789B2 (en) 2003-10-23
HK1043729B (zh) 2005-11-04
DE60019273T2 (de) 2006-01-19
KR20010102507A (ko) 2001-11-15
HK1043729A1 (en) 2002-09-27
BR0008784A (pt) 2001-12-26
IL145046A0 (en) 2002-06-30
NO20014292L (no) 2001-10-29
PL354143A1 (en) 2003-12-29
ES2238026T3 (es) 2005-08-16
EP1162993B1 (en) 2005-04-06
WO2000053216A3 (en) 2001-01-11
TR200102577T2 (tr) 2004-09-21
US20050129717A1 (en) 2005-06-16
CZ20013189A3 (cs) 2002-02-13
EP1162993A2 (en) 2001-12-19

Similar Documents

Publication Publication Date Title
CY1105585T1 (el) Χρηση των πολυπεπτιδιων casb616 και πολυνουκλεοτιδιων για τη θεραπεια του καρκινου
CY1113109T1 (el) Νεες ενωσεις
CY2013004I1 (el) Προϊοντα συζευξης auristatin και χρηση αυτων για θεραπεια καρκινου, αυτοανοσης ασθενειας ή μολυσματωδους ασθενειας
CY1111147T1 (el) Διαμεμβρανικο αντιγονο λεκτινης τυπου c εκφραζομενο σε καρκινο στον προστατη ανθρωπου και χρησεις αυτου
IL202332A0 (en) Liv-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer
CY1105211T1 (el) Φαρμακευτικοι συνδυασμοι που πepιλαμβανουν εναν ανταγωνιστη του υποδοχεα p2τ και μελαγατρανη
AP2006003537A0 (en) Use of polypeptides of the cupredoxin family in cancer therapy.
TR199800270T1 (xx) Kanser hastal�klar�n�n ilerlemesini �nlemede flukonazol kullan�m�.
CY1109812T1 (el) Αντιγονικα πολυπεπτιδια neisseira meningitidis (μηνιγγιτιδοκοκκου), αντιστοιχα πολυνουκλεοτιδια και προστατευτικα αντισωματα
CY1106525T1 (el) ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΜΕ hCG ΓΙΑ ΤΗΝ ΑΝΤΙΜΕΤΩΠΙΣΗ ΤΟΥ ΜΕΤΑΣΤΑΤΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΜΑΣΤΟΥ
ATE427967T1 (de) Spezifische antikírperfragmente fur das humane carcinoembryonic antigen (cea)
NZ500216A (en) Beta-amyloid peptide-binding proteins and pharmaceutical use
WO2003026494A3 (en) Galectins-1-and-4 in tumor development
BR0008917A (pt) Compostos
CY1105287T1 (el) Ορχεως - ειδικη ανθρωπινη svph1-8 πρωτεϊναση
AU1991901A (en) Pharmaceutical composition for treating and preventing human tumors, which express the tumor antigen mucin and/or the carcinoembryonic antigen (cea), and the use thereof
IT1318509B1 (it) Polimeri reticolati, utili per uso farmaceutico, medicale e cosmetico.
CY1108412T1 (el) Συνθεσεις εμβολιου που περιλαμβανουν omp85 πρωτεϊνες απο neisseria gonorrhoea και neisseria miningitidis
WO2001023417A3 (en) Human tumor-associated lak-4p related polynucleotides and polypeptides and their uses
WO2003042700A3 (en) Breast cancer associated polypeptide
WO2000043509A3 (en) Polynucleotides and their applications in diagnostics
ATE293693T1 (de) Moraxella catarrhalis antigen basb117
GB0121818D0 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
GB0118387D0 (en) Proteins,genes and their use for diagnosis and treatment of breast cancer
ITBO990449A0 (it) Apparato ginnico con massaggio della persona .